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Restrictive cardiomyopathies (RCMs) are a diverse group of myocardial diseases with a wide range of aetiologies, including familial, genetic
and acquired diseases and ranging from very rare to relatively frequent cardiac disorders. In all these diseases, imaging techniques play a
central role. Advanced imaging techniques provide important novel data on the diagnostic and prognostic assessment of RCMs. This
EACVI consensus document provides comprehensive information for the appropriateness of all non-invasive imaging techniques for the
diagnosis, prognostic evaluation, and management of patients with RCM.
...................................................................................................................................................................................................
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Introduction
Restrictive cardiomyopathies (RCMs) are a diverse group of myocar-
dial diseases with a wide range of aetiologies including familial, genetic,
and acquired diseases and ranging from very rare to relatively frequent
cardiac disorders. This diversity is also reflected in the inconsistent clas-
sification of RCM across guidelines1–3 and even in the term ‘restrictive’,
which is a functional characterization, unlike the morphological defin-
ition of the three other main types of cardiomyopathies, i.e. hyper-
trophic, arrhythmogenic right ventricular or dilated cardiomyopathies.4
Independently of the underlying cause, the pathophysiology, and
clinical presentation, the initial phenotypic diagnosis of RCM requires
imaging techniques. Many advances have occurred in the last decade
in the diagnostic and prognostic assessment of RCM. This EACVI
consensus document provides comprehensive information for the
appropriateness of all non-invasive imaging techniques for the diagno-
sis, prognostic evaluation, and management of patients with RCM.
This article was written in close collaboration between the
European Association of Cardiovascular Imaging (EACVI) and the
Working Group (WG) on Myocardial and Pericardial diseases of
the European Society of Cardiology (ESC). The types of RCM cov-
ered in this document are those included in the classification system
proposed by the WG on Myocardial and Pericardial diseases1 as well
as some non-sarcomeric hypertrophic cardiomyopathies (HCMs)
with a restrictive physiology that in previous classifications were
included in the RCM category, e.g. cardiac amyloidosis (CA).
Definition and classification of
RCM
RCM is the least common type of the cardiomyopathies, defined as
myocardial disorders in which the heart muscle is structurally and function-
ally abnormal in the absence of coronary artery disease, arterial systemic
hypertension, valvular disease, or congenital heart disease sufficient to
cause the observed myocardial abnormality.1
According to the historical World Health Organization (WHO)2
and the updated definition proposed by the ESC WG on Myocardial
and Pericardial Diseases in 2008,1 each cardiomyopathy type is
described by its clinical presentation. This approach is recommended
firstly because it is the starting point in everyday clinical practice, and
secondly because knowledge of aetiologies is still evolving, thus at
present an aetiological classification would not be conclusive.
RCM is defined by restrictive ventricular physiology in the
presence of normal or reduced diastolic volumes, with normal or
Multimodality imaging in restrictive cardiomyopathies 1091
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near-normal left ventricular (LV) systolic function, and normal or
near-normal wall thickness.1–5 Increased interstitial fibrosis may be
present. RCM constitutes a heterogeneous group of heart muscle
diseases with various causes (Table 1) that may be classified according
to very different criteria.
According to the main pathophysiological mechanism, RCM may
be subclassified into infiltrative or storage diseases (e.g. amyloidosis
and glycogen storage disease); obliterative or endomyocardial dis-
eases [e.g. endomyocardial fibrosis (EMF), related or not to
hypereosinophilia].
The WHO classification system was based on the distinction be-
tween primary and secondary myocardial disorders.2 Primary cardio-
myopathies were defined as either not caused by an identifiable agent,
e.g. idiopathic, or related to a primary myocardial cause. Secondary dis-
eases were related to systemic disorders affecting the myocardium
with a pathophysiological process starting outside of, e.g. unspecific to
the myocardium. The American Heart Association (AHA) proposed a
slightly different classification system in which the term ‘primary’ was
used to describe diseases in which the heart is the sole or predomin-
antly involved organ whereas ‘secondary’ is used to describe diseases in
which myocardial dysfunction is part of a systemic disorder.3
However, the challenge of distinguishing primary and secondary
disorders is illustrated by the fact that many diseases classified as
primary cardiomyopathies (e.g. glycogen storage disease, mitochon-
drial cytopathies) in the AHA classification can be associated with
major extra-cardiac manifestations. Conversely, pathology in many of
the diseases classified as secondary cardiomyopathies can predomin-
antly (or exclusively) involve the heart (e.g. EMF or Fabry disease car-
diac variant). In addition, the term of primary cardiomyopathy as an
idiopathic condition is no longer appropriate in a large group of pa-
tients since genetics has identified mutations in various genes such as
sarcomeric causes. Therefore, the ESC WG on Myocardial &
Pericardial Diseases proposed in 2008 to abandon the distinction be-
tween primary and secondary causes.1
As an alternative to this classification, the ESC Working Group on
Myocardial and Pericardial Diseases proposed to subclassify RCM
and other cardiomyopathies into (i) familial or genetic causes and (ii)
non-familial/non-genetic causes, because of the recent and increasing
knowledge about genetic causes of cardiomyopathies. This is espe-
cially illustrated in RCM related to CA that may be acquired (amyloid-
osis AL or senile amyloidosis) or genetically determined
(transthyretin and other genes mutations) and be included in the
non-sarcomeric HCMs as well as in the RCM.1 The latter ESC classifi-
cation will be used in this position paper.
Pathophysiology of RCM and
clinical presentation
Restrictive physiology is characterized by a pattern of LV filling in
which increased stiffness of the myocardium causes a precipitously
rise of LV pressure with only small increases in volume. On cardiac
catheterization, this phenomenon is characterized by a dip-and-
plateau contour of early diastolic pressure traces. The standard
echocardiographic features of ‘restrictive’ filling are described in
Section Echocardiography
Similarly, some patients with a restrictive physiology may have sig-
nificantly increased wall thickness such as patients with CA. RCM
should be differentiated from constrictive pericarditis (CP).6,7 (see
Section Main forms of RCM and value of imaging techniques).
Imaging modalities in RCM
Echocardiography
Echocardiography plays a key role for the recognition of RCM. The
echocardiographic diagnosis requires to differentiate RCM from CP.
RCM are usually characterized by normal or small LV cavity size
(<40 mL/m2) with preserved LV ejection fraction, bi-atrial enlarge-
ment, and diastolic dysfunction.5
Assessment of LV diastolic function and filling pressures is of utmost
value in RCM. In the recent joint American Society of
Echocardiography (ASE)/EACVI recommendations for the evaluation
of diastolic function by echocardiography,8 the four recommended vari-
ables to diagnose LV diastolic dysfunction and their abnormal cut-off
values are annular e’ velocity (septal e’ < 7 cm/s, lateral e’ < 10 cm/s),
average E/e’ ratio > 14, LA maximum volume index > 34 mL/m2, and
peak TR velocity > 2.8 m/s (Figure 1). Other valuable parameters to
identify the presence of elevated LV filling pressures are the ratio of pul-
monary vein peak systolic to peak diastolic velocity, or systolic time
.................................................................................................
Table 1 Main causes of RCM
Cause Familial/
genetic
Non-familial/
non-genetic
Apparently Idiopathic
Genetic origin X
Unknown origin X
Amyloidosis
AL/prealbumin X
Genetic (e.g. TTR) X
Senile X
Other infiltrative diseases (such as
Gaucher’s disease, Hurler’s disease)
X
Inflammatory cardiomyopathies with a
restrictive haemodynamic
component: Sarcoidosis, SSc
X
Storage diseases
Haemochromatosis X
Fabry disease X
Glycogen storage disease X
Pseudoxanthoma elasticum X
Radiation therapy X
Drugs X
Endomyocardial diseases (with or
without hypereosinophilia, carcinoid
disease, drug induced)
X (rare) X (frequent)
Miscellaneous (radiation, drug-induced,
e.g. antracycline toxicity, serotonin,
methysergide, ergotamine, mercurial
agents, and busulfan)
X
RCM, restrictive cardiomyopathy; TTR, transthyretin; SSc, systemic sclerosis.
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..velocity integral to diastolic time velocity integral < 1, and the changes
in E/A ratio with Valsalva manoeuver. The restrictive filling is considered
reversible if the change of E/A ratio during Valsalva is >_ 0.5 and fixed if it
is < 0.5 (more severe form).
The diagnosis of RCM does not equal the presence of restrictive
physiology. Patients with true RCM may present with a Grade I dia-
stolic dysfunction and move progressively to Grade II or III diastolic
dysfunction with worsening of their disease. The advanced stages of
RCM are characterized by typical restrictive physiology with a mitral
inflow E/A ratio > 2.5, DT of E velocity < 150 ms, IVRT < 50 ms,
decreased septal and lateral e’ velocities (3–4 cm/s), E/e’ ratio > 14, as
well as a markedly increased LA volume index (>50 mL/m2),8 this
advanced restrictive pattern being associated with the worst progno-
sis.9 Wall thickness is usually normal.
Some specific features may also help differentiate secondary RCM,
including several systemic conditions (diabetic cardiomyopathy,
scleroderma, EMF, radiation, chemotherapy, carcinoid heart disease,
metastatic cancers), from apparently idiopathic RCM (see Section
Main forms of RCM and value of imaging techniques). Ultrasonic tis-
sue characterization with integrated backscatter has been used to as-
sess myocardial texture, but is non-specific.10,11 Finally, two-
dimensional deformation imaging is useful for the assessment of LV
longitudinal dysfunction, which is frequently impaired in most forms
of RCM12 (see Section Main forms of RCM and value of imaging tech-
niques), and may help differentiating RCM form CP.13
Cardiovascular magnetic resonance
Cardiovascular magnetic resonance (CMR) imaging can contribute
importantly to the diagnosis of RCM and the differential diagnosis
from pericardial constriction.14 The CMR methods most commonly
used for the assessment of RCM include static (black blood) images,
cine and contrast enhanced imaging as well as parametric mapping.
Static images are used to delineate cardiac, pericardial and vascular
morphology. T1 and T2 weighted black blood images are sensitive to
different tissue characteristics and provide complementary informa-
tion. T1 weighted images show high signal from fat, as may for ex-
ample be seen in Fabry’s disease, while T2 weighted short tau
inversion recovery (STIR) images show high signal in myocardial oe-
dema, for example in acute sarcoidosis.
CMR allows accurate volumetric assessment of the heart and can
accurately measure chamber size and function.15 Typical cine CMR
images are averaged over several heart beats to maximize image qual-
ity and temporal resolution, but real-time imaging can also be per-
formed to demonstrate the typical septal shift during respiratory
manoeuvers and identify restrictive physiology.16 Velocity encoded
CMR in standardized imaging planes perpendicular to the atrio-ven-
tricular (AV) heart valves is used to demonstrate the typical restrict-
ive filling patterns of accentuated early filling and absent or reduced
late filling.17
A unique feature of CMR of relevance to the imaging of RCM is tis-
sue characterization with late gadolinium enhancement (LGE).
Following intravenous administration gadolinium-based contrast
agents are retained preferentially in tissues with an expanded extra-
cellular space, such as fibrosis, scar or infiltration. Characteristic pat-
terns of contrast enhancement can be observed in several of the
RCMs, contributing to the differential diagnosis of Fabry disease,
amyloidosis, EMF, and sarcoidosis (Figure 2). In many of these condi-
tions, the presence of LGE also has important prognostic
Figure 1 ASE—EACVI criteria for grading LV diastolic function in patients with depressed LVEF and patients with myocardial disease and normal
LVEF after consideration of clinical and other two-dimensional data (from reference 8 with permission).
Multimodality imaging in restrictive cardiomyopathies 1091b
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relevance.18–20 Finally, parametric mapping methods have increasing
applications in RCM and allow quantitative measurement of tissue
characteristics. T2*-weighted CMR is now the method of choice to
detect and quantify myocardial iron content in iron deposition car-
diomyopathy and to guide appropriate therapy.21 A low myocardial
T2* value in this context is currently considered the most powerful
marker of adverse outcome.22 More recently, T1 mapping has been
used to quantify the extent of myocardial inflammation and fibrosis.
Native T1 relaxation times, as measured with T1 mapping without
the need for contrast agent administration, are altered in several con-
ditions including amyloidosis and may have incremental value over
LGE imaging.23 The combination of native and post-contrast T1 map-
ping allows an estimation of the myocardial extracellular volume
(ECV) fraction, which in amyloidosis can even show differences in
subtypes of the disease.24 T1 mapping may also be useful in iron over-
load instead of the more established T2* mapping.25
Cardiac computed tomography
The key advantage of computed tomography (CT) is its high-spatial
resolution and the anatomical detail it provides. However the associ-
ated radiation exposure largely limits this modality to static imaging,
precluding dynamic analyses of LV haemodynamics, filling, or relax-
ation. Nevertheless CT is well suited to identifying the anatomic fea-
tures of impaired cardiac filling that characterize RCM. These include
dilatation of the atria, coronary sinus and inferior vena cava and the
presence of pulmonary congestion and pleural effusions. These fea-
tures are also observed in a range of other conditions and the pre-
dominant role of CT with respect to RCM is in the exclusion of these
alternative diagnoses. In particular, CT is well suited to detecting the
thickening and calcification of the pericardium most commonly asso-
ciated with CP.26 Similarly CT allows assessment of extra-cardiac in-
volvement in systemic conditions such as sarcoidosis (e.g. pulmonary
nodules, pulmonary fibrosis, and lymphadenopathy) or amyloidosis
(e.g. inhomogeneous hepatomegaly, diffuse lung parenchymal in-
volvement, small kidneys) further aiding in the differential diagnosis.
When other imaging modalities are not available, CT may be useful
in evaluation of patients with RCM, owing to its ability to measure LV
wall thickness and mass, detect regional wall thickening,27 regions of
replacement fibrosis,27,28 and measure myocardial ECV fraction by
equilibrium contrast-enhanced CT to assess diffuse fibrosis.29 These
advances may increase the clinical utility of CT in the future clinical as-
sessment of patients with RCM, particularly when echocardiography
and CMR are non-diagnostic or contraindicated.
Nuclear imaging
Nuclear imaging modalities have a potential clinical role in two forms
of RCM: amyloidosis and sarcoidosis (see Sections Cardiac amyloid-
osis and Non familial/non-genetic RCM: inflammatory cardiomyopa-
thies with a restrictive haemodynamic component). Nuclear imaging
modalities have the advantage of specific targeted molecular imaging.
Positron emission tomography (PET) has the technical advantages of
high-spatial resolution, robust built-in attenuation correction, quanti-
tative analysis, and low-patient radiation exposure, whereas single
photon emission computed tomography (SPECT) has the advantage
of a robust, cheaper, and well-validated camera system.
There are increasing data on the role of nuclear tracers with
SPECT and more recently with PET for early identification and differ-
ential diagnosis of CA, particularly transthyretin-related amyloidosis
(ATTR)
Radiolabelled SPECT phosphate derivatives, initially developed as
bone-seeking tracers, were noted to localize to amyloid deposits
using [99mTc]-diphosphanate.30 In clinical practice, the most used
SPECT tracers are: 99mTc-DPD mainly in Europe and Asia and
99mTc-PYP in the USA. Their main advantage is avid uptake by
ATTR and minimal uptake with the light-chain (AL) amyloidosis sub-
type, providing one of the best non-invasive ways to differentiate
these subtypes of CA.31,32
The imaging technique is simple. Briefly, after administering 740
MBq of 99mTc-DPD, or [99mTc]-HDP,32,33 or of 99mTc-PYP34
intravenously, a whole-body scan is performed 3 h or 1 h later (anter-
ior and posterior projections). If there is active uptake in the heart,
chest SPECT is performed. The analysis is performed by semi-
quantitative visual scoring of the cardiac as compared to the bone up-
take (scores from 0 to 3) and by computing the ratio, after correction
for background counts, of the mean counts in the heart region over
the mean counts in the contralateral chest (H/CL ratio).
Other nuclear imaging approaches have been recently proposed
for the diagnosis and prognostic stratification of patients with sus-
pected amyloidosis.31 PET imaging using new amyloid tracers like the
[11C]-labelled Pittsburgh Compound B (PiB) or [18F]-florbetapir is
promising and under early clinical investigation. The use of neuronal
imaging by [123-I]-MIBG SPECT has been suggested for early recog-
nition of cardiac involvement and prognostic stratification of individ-
uals with TTR mutation.34
The inflammatory nature of cardiac sarcoidosis (CS) renders PET
useful for its diagnosis, as [18F]FDG accumulates in inflammatory cells
Figure 2 Seventy-four year-old patient presenting with breath-
lessness. Cine CMR showed global LV hypertrophy, impaired longi-
tudinal LV shortening, and dilated atria. Late gadolinium enhanced
CMR in the figure showed diffuse endocardial enhancement consist-
ent with infiltrative disease. Subsequently, the patient was found to
have amyloidosis. LV, left ventricle; RV, right ventricle; LA, left
atrium; RA, right atrium.
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..in the heart. FDG is preferred in combination with a perfusion tracer
to improve specificity due to better match/mismatch pattern recog-
nition. Unlike in CMR, there is no distinct pattern of FDG uptake that
is pathognomonic for CS, though focal or focal on diffuse uptake is
suggestive of the disorder.35 At present, [18F]FDG-PET appears to be
more sensitive but less specific than CMR36 and its use seems most
appropriate in patients who have contraindications to CMR, incon-
clusive findings on CMR or where CMR is not available also to moni-
tor response to therapy. The development of FDG PET/MR
techniques offers the ability to assess LV wall function, the pattern of
myocardial injury and disease activity in a single scan.37 (Figure 3).
In summary, several imaging techniques are available in the evalu-
ation of RCM, all of which have both advantages and limitations.
Table 2 summarizes the value of different imaging modalities in
various forms of RCM. Although non-invasive techniques are suffi-
cient in most cases, final histologic diagnosis may sometimes be ne-
cessary, and may be obtained by biopsies specimens from the heart
[endomyocardial biopsies (EMB)] or other organs. Figure 4 illustrates
by histology and immunohistology different disease entities of RCM
which will be discussed in the following chapters.
Main forms of RCM and value of
imaging techniques
Apparently idiopathic RCM
Apparently idiopathic RCM may be caused by mutations in sarco-
meric disease genes and may even coexist with HCM in the same
Figure 3 Patient with acute myocardial sarcoidosis (from reference 37 with permission). Patient (62-year-old male) followed for histologically pro-
ven pulmonary sarcoidosis treated by steroids for 10 years presented with symptoms of acute breathlessness. Cardiac involvement was suspected.
LGE-CMR (A) images showed patchy LGE of the lateral wall. Matched FDG-PET (B) and fused FDG-PET/MR (C and D) images obtained in short-axis
view showed intense uptake in exactly the same territory as the pattern of injury on CMR (maximum standardized uptake value of LGE territory/
blood pool uptake ratio = 2.7). A two-chamber cine CMR (E) sequence showed mild hypokinesis of the lateral wall and mild overall LV systolic im-
pairment (LV ejection fraction = 52%). Maximum intensity projection FDG-PET (F) cine view confirmed abnormal myocardial uptake without evi-
dence of increased activity outside of the heart.
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family38–40 and may require EMB (to exclude CA), family screening,
and genetic investigations. Most affected individuals have severe signs
and symptoms of heart failure. Several studies have reported that
66–100% die or receive a cardiac transplant within a few years of
diagnosis.
The echocardiographic diagnosis is one of restrictive physiology
and mostly preserved LV ejection fraction. Typically, idiopathic RCM
is characterized by diastolic dysfunction with apparently preserved
systolic function, dilated atria, and the absence of ventricular hyper-
trophy or dilatation (Figure 5 and see Supplementary data online,
Videos S1 and S2). Longitudinal function may be decreased; the right
ventricle may be involved but there is no ‘pathognomonic’ echocar-
diographic pattern of apparently idiopathic RCM. CMR with LGE
may facilitate the diagnosis of infiltrative myocardial disease, and is
thus particularly useful for ruling out a particular cause of RCM.41
Cardiac amyloidosis
CA is one of the most frequent causes of RCM and may be genetic/fa-
milial (ATTR) or non-genetic non-familial (AL/prealbumin, senile).
The diagnosis requires awareness, expertise and a high level of clin-
ical suspicion, with integration between clinical, electrocardiographic,
and echocardiographic data. The ‘mismatch’ between the presence
of LV hypertrophy (LVH) in echocardiography and its absence on the
ECG (no LVH, absolute, or relative low-voltage QRS) is suggestive of
CA and is often the first disease ‘red flag’.42,43 Typical echocardio-
graphic findings in CA patients include (Figure 6A) a non-dilated LV
with moderate concentric LVH and a ‘granular sparkling’ appearance
of the myocardial texture, valvular thickening (mainly the AV valves),
biatrial dilatation, right ventricular free wall hypertrophy, inter atrial
septum infiltration (loss of physiological echo drop-out), and mild
pericardial effusion.44 In the early stages of the disease, CA may pre-
sent as asymmetrical septal hypertrophy, sometimes with LV outflow
tract obstruction and can then be wrongly diagnosed as HCM. The
presence of intra-atrial thrombus also seems to be relatively frequent
in patients with CA, even in sinus rhythm.45
Patients often show (Figure 6B) advanced diastolic dysfunction
(Grade II or III) and increased LV filling pressures. The classical trans-
mitral restrictive pattern may only be seen at advanced disease stages.
The typical tissue Doppler imaging (TDI) pattern of CA, with low sys-
tolic (s’) and diastolic (e’, a’) myocardial velocities. Of note, E/e’ ratio
is usually abnormally increased even in the presence of LV abnormal
relaxation pattern (diastolic dysfunction Grade I).46
LV systolic dysfunction is also a common finding in this disease. In
early stages, despite preserved LV ejection fraction, longitudinal func-
tion is abnormal (abnormal long axis systolic velocities (s’) and strain)
(Figure 7A) as well as myocardial contraction fraction, a recently
described systolic parameter.47
Two-dimensional speckle-tracing echocardiography (2D-STE) is
important, as many systolic strain parameters (longitudinal, circum-
ferential, radial) are abnormal in CA, particularly in the longitudinal
axis, typically with prominent involvement of LV basal segments and
apical sparing48 (Figure 7B), reflecting the predominant deposition of
amyloid in basal segments. The combination of a prominent reduc-
tion of longitudinal strain in LV basal segments with increased E/e’
ratio suggests CA in early stages.49
Multiple echocardiographic parameters have been associated with
adverse outcomes in CA, including M- mode and two-dimensional
data (maximal wall thickness, LV fractional shortening and LV ejection
fraction, right ventricle dilatation), blood pool Doppler data (restrict-
ive filling pattern, myocardial performance index, Tissue Doppler
....................................................................................................................................................................................................................
Table 2 Value of different imaging modalities in various forms of RCM
TTE TDI and strain imaging CMR Nuclear imaging Cardiac CT PET
Apparently idiopathic RCM þþþ þþ þþ 0 þ 0
Cardiac amyloidosis þþþ þþþ þþþ þþþ þ þ
Other causes of familial/genetic RCM
Haemochromatosis þþþ þ þþþ þ 0 0
Fabry cardiomyopathy þþ þþ þþþ 0 0 0
Glycogen storage disease þþ þþ þþ þ 0 0
Pseudoxanthoma elasticum þþ þ þþ þ 0 0
Inflammatory CM with a restrictive component
Cardiac sarcoidosis þ 0 þþ þþ þ þþþ
Systemic sclerosis þþ þþ þþ þ 0 0
Radiation therapy and cancer drug therapy induced RCM
Cardiac toxicity of radiation therapy þþ þ þþ þ 0 0
Cancer drug induced RCM þþþ þþ þþ 0 0 0
Endomyocardial RCMs
Endomyocardial fibrosis þþþ þ þþþ 0 0 0
Hypereosinophilic syndrome þþþ þ þþþ 0 0 0
Carcinoid heart disease þþþ 0 þþ 0 0 0
Drug-induced endomyocardial fibrosis þþþ 0 þþ 0 0 0
Differential diagnosis with CP þþþ þþ þþ 0 þþþ 0
RCM, restrictive cardiomyopathy; TDI, tissue Doppler imaging; CMR, cardiovascular magnetic resonance; PET, positron emission tomography; CT, computed tomography; TTE,
transthoracic echocardiography.
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.derived data (myocardial velocities, long axis velocity gradient, peak
longitudinal systolic basal antero-septal strain > -7.5%),50 and 2D-STE
parameters [global longitudinal strain (GLS), mid-septum systolic lon-
gitudinal strain, apical LS< -14.5%].51,52
CMR is often used after CA is suspected by echocardiography to
confirm or refute the diagnosis, and in experienced hands represents
a powerful tool with important diagnostic and prognostic implica-
tions. Cine images may demonstrate typical anatomical features like
Figure 4 Imaging of RCM at the cellular level. Different disease entities of RCM are visualized by histology and immunohistology. Sarcoidosis with
typical granulomas, fibrosis (blue tissue) (A, Masson trichrome stain), and numerous CD68þmacrophages and giant cells (B, immunohistochemistry).
Hypereosinophilic syndrome with myocyte necrosis, eosinophilic granulocytes, (C, Giemsa stain) and CD68þmacrophages (D, immunohistochemis-
try). Storage diseases: haemochromatosis with iron containing myocytes (E, Prussian blue) and fibrosis (F, Sirius red). AL-amyloidosis (G, AL-amyloid
immunohistochemistry (green), H, Kongo red). Glycogenosis with hypertrophic, vacuolated myocytes, and fibrosis (I, Masson trichrome stain) and
large amounts of glycogen (J, PAS stain (red)) (A and B: x100; C–J: x200).
Multimodality imaging in restrictive cardiomyopathies 1091f
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcim
aging/article-abstract/18/10/1090/3828464 by guest on 06 June 2019
Figure 5 Multimodality imaging findings in three patients with apparently idiopathic RCM. (A) (TTE) and (B) (CMR) Impressive dilatation of both
atria predominating on the right cavities, contrasting with small LV and RV cavities (Supplementary data online, Video S1). (C) More classical form of
idiopathic RCM with normal ventricular systolic function and severe atrial dilatation. RA, right atrium; RV, right ventricle; LV, left ventricle; LA, left
atrium (Supplementary data online, Video S2). (D) Multimodality imaging in a severe RCM. Patient in atrial fibrillation and a pace maker for severe AV
block. Huge atria that can be seen on the CT, (1) the chest X-ray, (2) and the Echocardiography. (6) There is a severe tricuspid regurgitation (5) and a
severe alteration of the longitudinal systolic and diastolic function as shown by the tissue Doppler (5) and the strain data. (4) Extensive circumferential
subendocardial late gadolinium enhancement is observed by CMR (3).
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thickened LV wall, biatrial enlargement, reduced long-axis shortening,
and pleural or pericardial effusion. The presence of amyloid protein
in the myocardial interstitium is associated with abnormal
gadolinium-chelate contrast kinetics and characteristic patterns of
contrast distribution. LGE images typically show circumferential sub-
endocardial contrast enhancement or bilateral septal subendocardial
LGE with dark mid-wall (zebra pattern) (Figure 8A),53,54 but other pat-
terns of enhancement have also been described. In atypical cases,
other differential diagnoses should be considered such as HCM or
Fabry’s disease. Cardiac involvement can extend to the right ventricle
and atrial walls, as potentially detected by LGE. The extent of myo-
cardial LGE correlates with New York Heart Association functional
class, LV wall thickness, lower ECG voltage, and cardiac biomarkers
(troponins, brain natriuretic peptide).55 With more advanced disease,
amyloid infiltration may be transmural with corresponding global en-
hancement on LGE images, which is an independent predictor of
poorer outcomes, over stroke volume and pro-NT brain natriuretic
peptide.19
Figure 6 (A) Two-dimensional echocardiography in a 52-year-old male with CA, AL type, associated with plasma cell dyscrasia: non-dilated LV
with moderate concentric LVH with ‘granular sparkling’ appearance, mitral valve thickening, mild to moderate biatrial dilatation, inter atrial septum in-
filtration (loss of physiological echo drop-out) and mild pericardial effusion. RA, right atrium; RV, right ventricle; LV, left ventricle; LA, left atrium; Ao,
aorta. (B) Diastolic function in the same patient: E/A1 (PWD transmitral inflow), low-systolic and diastolic myocardial velocities (TDI), E/e’ =25, re-
flecting high-LV filling pressures.
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Figure 7 (A) Two-dimensional-STE apical longitudinal view in systemic AL amyloidosis: severely abnormal longitudinal strain, particularly in the
basal and medial LV segments. (B) Systemic AL amyloidosis, multiple myeloma: 2D-STE, relative apical sparing, typical of CA. Note the abnormal GLS
(-4.9%).
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Amyloid deposits increase the longitudinal relaxation time (T1)
magnetic property of the heart. Thus, myocardial non-contrast T1
values are longer in CA than in controls, a finding with higher sensitiv-
ity for detecting early subclinical cardiac involvement than LGE.23
ECV estimation from pre- and post-contrast T1 mapping has been
used to quantify interstitial amyloid deposition which appears to be
more extensive in transthyretin amyloidosis (TTR) than in immuno-
globulin AL.56 The addition of parametric mapping to standard CMR
images is promising to be a powerful and quantitative diagnostic tool
that also allows differential diagnosis from other diseases with similar
phenotypic expression.
Scintigraphy employs molecular-targeted radiolabelled compounds
to detect systemic and organ-specific amyloid deposits. Scintigraphy is
a valuable alternative to CMR particularly for patients with ATTR
amyloidosis due to its very high sensitivity. Scintigraphy may also be
used following an inconclusive CMR study, or for phenotyping CA
(ATTR vs. AL) or in the differential diagnosis with sarcomeric
HCM.57,58 The [99mTc]-labelled bisphosphonate compounds pyro-
phosphate (PYP)58 and 3,3-diphosphono-1,2-propanodicarboxylic
acid (DPD),59 and hydroxydiphosphonate (HDP)33 (which are rou-
tinely used as bone scintigraphy agents) bind through unknown mech-
anisms to amyloid protein. All have proven very sensitive for detecting
Figure 8 (A) CMR in a 79-year-old patient with CA showing mild septal hypertrophy (16 mm), biatrial enlargement, and diffuse patchy uptake of
gadolinium throughout the mid-ventricular and basal segments of the septal, anterior, and inferior wall with sparing of the apicolateral wall. (Note
small areas of bilateral subendocardial LGE in the septal wall characteristic of CA (arrows) and LGE in the right ventricular free wall and the left
atrium). RA, right atrium; RV, right ventricle; LV, left ventricle; LA, left atrium. (B) Late-phase planar 99mTc-DPD-scintigraphy (anterior views) in a pa-
tient with ATTR amyloidosis (A) and a normal control (B). Note intense cardiac uptake in (A) demonstrating CA. Moreover, increased soft tissue up-
take particularly in the shoulder region and the abdominal wall with obscuring of bone uptake can be observed as a typical pattern of ATTR
amyloidosis.
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..cardiac involvement in ATTR amyloidosis with reported sensitivities
up to 100% on late phase planar scintigraphy. Typical uptake patterns
besides cardiac uptake in ATTR amyloidosis include increased soft tis-
sue uptake (mainly muscular uptake in the gluteal, shoulder, chest, and
abdominal wall regions) with obscuring of bone uptake (Figure 8B).
However, in AL amyloidosis, cardiac uptake is found in less than half of
patients and is generally less intense (likely due to the lower concen-
tration of calcium-containing products in AL amyloid). Additionally, AL
patients have generally no muscular [99mTc]-DPD or [99mTc]-HDP
uptake while visceral uptake (liver, spleen) may be more common.
Even if there are not yet large comparative studies, the diagnostic
performance of nuclear imaging for CA is established. In general,
[99mTc]-DPD can differentiate subtypes60 and can be more sensitive
than CMR33 or echocardiography in diagnosing early disease being an
independent prognostic marker.61 In a recent study by Bokhari
et al.58 using 99mTc-PYP, while patients with AL had some uptake,
the visual score was significantly less than in patients with ATTR,
allowing the differentiation between ATTR and AL amyloidosis with
97% sensitivity and 100% specificity.
Hence, whole body planar DPD and HDP scintigraphy may help to
phenotype CA particularly through differentiating ATTR from AL
amyloidosis (or from sarcomeric HCM, where no DPD uptake is
seen), which often have overlapping imaging features on echocardiog-
raphy and CMR, but very distinct clinical course and prognosis.
Moreover, a recent comparison of [99mTc]-DPD scintigraphy and
LGE showed that despite a general good agreement between both
techniques, LGE may sometimes underestimate cardiac amyloid
burden.33 Finally, myocardial tracer uptake on scintigraphy is corre-
lated with disease severity (measured by circulating troponin and LV
wall mass), and has been shown to be a powerful prognostic deter-
minant of outcome in ATTR CA.32,61
Recent investigations found that bone scintigraphy enables the
diagnosis of cardiac ATTR amyloidosis to be made reliably without
the need for histology in patients who do not have a monoclonal
gammapathy.62 The algorithm proposed (Figure 9) that cardiac ATTR
amyloidosis can be reliably diagnosed in the absence of histology pro-
vided an echocardiogram or CMR is suggestive of amyloidosis, car-
diac uptake is present on scintigraphy and there is absence of a
detectable monoclonal gammapathy. Histological confirmation and
typing of amyloid should be sought in all cases of suspected CA in
which these criteria are not met.
In summary, all these imaging techniques are useful and give add-
itional information, including echocardiography, nuclear techniques
and CMR (Table 3),63 but also EMB and genetic testing, to differenti-
ate ATTR mutant from wild type. Figure 10 illustrates the value of
multimodality imaging in a patient with CA.
Other causes of familial/genetic RCM
Haemochromatosis
Iron overload cardiomyopathy (IOC) results from iron accumulation
in the myocardium mainly because of genetic disorders of iron me-
tabolism (primary haemochromatosis) or multiple transfusions (such
as in thalassaemia or myelodysplastic syndromes).
Figure 9 Diagnostic algorithm for patients with suspected amyloid cardiomyopathy (from reference 62 with permission). AApoA1, apolipoprotein
A-I; DPD, 3,3-diphosphono-1,2-propanodicarboxylic acid; HDMP, hydroxymethylene diphosphonate; PYP, pyrophosphate.
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In the early stages, myocardial iron overload (MIO) causes diastolic
LV dysfunction.64 If no effective iron chelation is instituted in time,
the majority of patients develops LV dilatation and reduced LV ejec-
tion fraction (EF) (dilated phenotype).65 In a minority of cases with
severe MIO, restrictive LV dysfunction can lead to pulmonary hyper-
tension, right ventricular dilatation, and right-sided heart failure with
preserved LVEF (restrictive phenotype).66
Echocardiography is a useful modality in the follow-up of iron-
loaded patients. A pseudonormalized pattern of transmitral inflow is
frequently encountered and may be unmasked by tissue Doppler.67
LV diastolic dysfunction and reduced EF may both be masked by an
anaemia-induced high-cardiac output state in haematologic patients.
There are few data relating diastolic function to outcome in
haemochromatosis.68
However, due to the lower accuracy in quantifying biventricular
systolic function and the lack of parameters able to predict MIO reli-
ably, echocardiography is only the second-line imaging method after
CMR.69,70
The method of choice for assessing IOC is CMR, which allows
tissue characterization including quantification of MIO. The para-
magnetic effect of iron-loaded myocardium affects T1, T2, and T2*
relaxation times which can be used to calculate MIO. The best vali-
dated method for quantifying MIO is T2* mapping. T2* values cor-
relate closely with hepatic and myocardial iron content and
correlate better with LV dilatation and LV dysfunction than serum
ferritin or liver iron concentration. A T2* value of < 20 ms at 1.5
Tesla, typically measured in the interventricular septum, is used as
a conservative cut-off for segmental and global heart iron overload
and patients with the lowest T2* values have the highest risk of de-
veloping arrhythmia and heart failure. T2* CMR has revolutionized
IOC management with the death rate in patients with thalassaemia
falling dramatically in countries where T2* CMR has been adopted.
In the assessment of IOC, the first cardiac T2* assessment should
be performed as early as possible and the effectiveness of iron che-
lation71 and reversal of MIO can be reliably guided by follow up
scans.72 A multislice approach can detect the uneven distribution
of MIO, allowing early identification of patients at risk of cardiac
complications.73
T2* is dependent on field strength and sensitive to field inhomo-
geneity. T2 and T1 mapping techniques offer some advantages over
T2* and have been compared with standard methods, with initial
studies showing close correlation with T2*.
In patients where the diagnosis is unclear, a multiparametric CMR
approach that evaluates cardiac function, myocardial fibrosis and
oedema may allow further clarification of the underlying mechanisms
leading to the LV dysfunction.74
In summary, cardiac involvement is frequent in haemochromatosis.
CMR is the main imaging technique for diagnosis and follow-up of
cardiac haemochromatosis, allowing both reliable measurement of
LV and RV dimension and function and tissue characterization includ-
ing quantification of MIO.
Fabry cardiomyopathy
Cardiac involvement is very common and is the most frequent cause
of death not only in haemizygote males but also in female heterozy-
gote carriers with a-Gal A deficiency, with a reduction of life expect-
ancy of approximately 20 and 15 years respectively.75 The heart may
be the only organ affected in the classic phenotype of Fabry disease,
and this is designated the ‘cardiac variant’.76
Cardiovascular manifestations include renovascular and systemic
hypertension, aortic root dilatation, mitral prolapse, and congestive
heart failure.77 Fabry cardiomyopathy mainly consists of progressive
LVH, which may cause substantial morbidity and contribute to the
reduced life expectancy of affected patients, both male and
female.78,79
LVH is a hallmark of Fabry cardiomyopathy.80 In patient populations
with HCM, the prevalence of Fabry disease ranges from 0 to 12%, de-
pending on the patient selection criteria used, but is close to 1% in the
largest series.81 LVH is generally symmetrical, although asymmetric
septal hypertrophy has been described, and the condition can mimic
the phenotypical and clinical features of HCM, including obstructive
HCM.82 Typically, the echocardiogram shows marked increases in
wall thickness and ventricular dilatation later in the disease process.
Valve leaflet thickening can be seen, and this produces valve impair-
ment that usually does not require surgical treatment.83
....................................................................................................................................................................................................................
Table 3 Multimodality imaging in the differential diagnosis between HCM and CA (from Cardim et al.63)
Imaging data HCM Cardiac amyloidosis
Echo, CMR, cardiac CT
LVH Severe, asymmetric Moderate, concentric, ‘sparkling’
Left ventricular outflow tract obstruction Frequent Rare (may exist in early stages)
Pericardial effusion Rare Frequent
IAS hypertrophy Rare Frequent
Apical sparing Rare Frequent
CMR
LGE RV insertion points, intramural Diffuse, subendocardial (global or segmental)
T1 mapping Under research Work in progress; typical patterns
CNI
99mTc-DPD uptake No Yes (TTR—senile and familial
CMR, cardiovascular magnetic resonance; HCM, hypertrophic cardiomyopathy; LVH, left ventricular hypertrophy; LGE, late gadolinium enhancement; TTR, transthyretin.
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Echocardiography using TDI can detect the first signs of myocar-
dial damage in a patient with Fabry cardiomyopathy and normal car-
diac wall thickness.84 Furthermore, TDI studies have been shown to
be useful in detecting cardiac involvement in female carriers with no
systemic manifestations of Fabry disease. A reduction of TDI veloc-
ities may represent the first sign of initial intrinsic myocardial
Figure 10 Multimodality imaging in a patient with familial TTR amyloidosis. (A) Two-dimensional echo long-axis view showing LV hypertrophy and
pericardial effusion (Supplementary data online, Video S3). (B) Apical sparing by two-dimensional strain (Supplementary data online, Video S4). (C)
Intense cardiac uptake on 99mTc scintigraphy. (D) CMR confirming LV hypertrophy and pericardial effusion (Supplementary data online, Video S5).
RV, right ventricle; LV, left ventricle; LA, left atrium; Per, pericardial effusion.
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impairment.85 These reduced TDI velocities in mutation positives
without LVH are consistent with the hypothesis that myocardial dys-
function precedes LVH.86
CMR with LGE may be useful in the non-invasive recognition of
myocardial fibrosis, in the context of cardiac involvement of Fabry
disease.87 The LGE pattern of distribution helps in the differenti-
ation between HCM and Fabry cardiomyopathy.18 Patients with
Fabry cardiomyopathy typically present with a pattern character-
ized by the involvement of the inferolateral basal or mid-basal seg-
ments.87 Furthermore, the myocardial T2 relaxation time is
prolonged in patients with Fabry disease compared with that in
HCM patients, and its measurement could be complementary to
the LGE technique. More recently, native T1 mapping was shown
to be the most reliable technique to differentiate Fabry cardiomy-
opathy from all the other LVH phenocopies, by demonstrating a
low native T1 value of the affected myocardium (whilst other LGE
area of different disease would display a high native T1 values).18
This important difference is due to the characteristic fatty nature of
the infiltration in Fabry disease.
Finally, for most males with Fabry disease, the diagnosis can be
made by measuring leucocyte and plasma a-Gal activity, while genetic
testing is useful in patients with normal levels of enzyme activity.18 A
familial screening should be performed in patients with Fabry’s dis-
ease (Figure 11).
In summary, cardiac involvement is frequent in Fabry disease and is
associated with worse outcome. Imaging techniques, especially TDI
and CMR, allow a comprehensive evaluation of cardiac involvement,
even before morphological manifestations such as hypertrophy
develop.
Glycogen storage disease
Glycogen storage disease is defined as the absence or deficiency of
one of the enzymes responsible for making or breaking down glyco-
gen in the body. The enzyme deficiency causes either abnormal tissue
concentrations of glycogen or incorrectly or abnormally formed
glycogen.88,89 There are 11 different types of glycogen storage dis-
eases causing different forms of heart failure. Most well-known are
Danon and Pompe diseases.80,90,91
Danon cardiomyopathy is progressive and typically manifests a
hypertrophic phenotype, with preserved LVEF and normal cavity di-
mensions early in the course of disease, and later progression to
dilated features in 11–12% of men.89 HCM is predominant in male pa-
tients, whereas an equal prevalence of hypertrophic and dilated car-
diomyopathy is seen in female patients.90
Echocardiography demonstrates increased LV mass and wall
thickness although LV systolic function is preserved. Taking into
consideration the possible progress to cardiac failure, serial echo-
cardiograms with attention to LV thickness and mass are important
in the care of these patients.91,92 Echocardiography is also the
standard method to evaluate the cardiac response to enzyme re-
placement therapy.
Typical findings in CMR consist of significantly reduced LV global
function and increase of LV end-diastolic and end-systolic volumes.
Perfusion defects, mainly subendocardial, are visible in almost all seg-
ments on rest first-pass perfusion images. They may be obvious in the
infero-septal segments and partly transmural in the lateral and
anterior walls. LGE appears to be a rare finding in Pompe disease but
when present, is seen in the subendocardium and in places transmur-
ally in the anterior and lateral walls.93,94
A diagnosis of Danon disease is always confirmed by EMB results.
99mTc-methoxyisobutylisonitrile myocardial imaging has also been
employed as an imaging diagnostic test for glycogen storage disease,
to detect myocardial damage as a non-invasive method. There has
been a positive rate of detection of damage with G-MPI of 77.8%.95
Other storage/infiltrative diseases (Gaucher disease, mucopolysac-
charidoses) may be rarely associated with cardiac involvement.96,97
Pseudoxanthoma elasticum
Pseudoxanthoma elasticum is a rare, inherited connective tissue dis-
order associated with coronary and peripheral arterial disease and
accelerated atherosclerosis in medium sized arteries.98 Cardiac in-
volvement may start as a diffuse arteriopathy secondary to elastic
fibre dysgenesis, involving the small intramural coronary vessels
(‘small-vessel disease’) and it may reach the clinical presentation of
congestive heart failure, even though—quite often—with normal epi-
cardial vessels.99
Echocardiography detects impaired LV systolic and diastolic func-
tion.100 Other imaging modalities—as functional tests—such as per-
fusion CMR or nuclear myocardial perfusion imaging, may be useful
to demonstrate early coronary involvement and/or the direct conse-
quences of ultrastructural defects of the elastic tissue of the heart.
Increased awareness for silent ischaemia is recommended.98,101
An important study with arterial stiffness evaluation demonstrates
the early detection of accelerated atherosclerosis and the impair-
ment of the elastic properties of the aorta. A lower elasticity in large
arteries, a higher cardiac output and a higher total vascular imped-
ance were observed in patients with pseudoxanthoma elasticum with
respect to the control group.101
Non-familial/non-genetic RCM:
inflammatory cardiomyopathies with a
restrictive haemodynamic component:
Cardiac sarcoidosis
Sarcoidosis is a multisystem inflammatory granulomatous disease of
unknown origin. CS is frequently isolated.102 Its diagnosis is difficult
and has benefited from the use of multimodality imaging.
Although echocardiography is not the method of choice for the
diagnosis of CS, it can offer very useful information in some cases.103
An unexplained reduced LV ejection fraction < 40% in a patient with
a histological diagnosis of extra-CS is suggestive of CS.104
Characteristic echocardiographic changes suggestive of CS are: wall
thickness > 13 mm (due to granulomatous expansion), or < 7 mm
(due to fibrosis), aneurysmal dilatation especially at the level of the in-
ferior and posterior walls,105 regional wall motion abnormalities
without any specific coronary distribution, interspersed with normo-
kinetic segments.106
CMR is one of the imaging modalities recommended for the diag-
nosis of CS in current guidelines103 and CMR may be more sensitive
for cardiac involvement than currently used clinical criteria.107
Myocardial inflammation may be identified by T2 STIR images and
early contrast enhancement while areas of fibrosis are detected by
LGE108 (Figure 12). The typical pattern of CS on LGE is patchy focal
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..enhancement sparing the endocardial border, not following a coron-
ary artery distribution,109 and involving mainly the basal and lateral
LV walls.110 Single or often multiple lesions are seen and other, more
atypical LGE patterns have also been described. Importantly, no LGE
pattern is pathognomonic for CS. Moreover, CMR offers prognostic
information: myocardial scar determined by LGE is a predictor for
ventricular arrhythmia and sudden cardiac death in patients with
sarcoidosis.111
Nuclear imaging has also an important role in the assessment of
CS. Although the major diagnostic criteria for CS include [67Ga]-
citrate scintigraphy, its sensitivity for CS is significantly lower than
[18F]FDG-PET/CT.112 For this reason [18F]FDG-PET/CT have cur-
rently replaced [67Ga]-scintigraphy in the majority of centres being
nowadays the most commonly used imaging test for detecting myo-
cardial inflammation. Advantages of [18F]FDG-PET/CT over [67Ga]
includes favourable tracer kinetics, lower radiation exposure, and
better quality images.113 Active sarcoid lesions present increased
[18F]FDG uptake on PET/CT imaging due to utilization of glucose as
an energy source by inflammatory cell in infiltrates.114 However,
[18F]FDG-PET/CT has not been officially adopted in the diagnostic
Figure 11 Familial Fabry’s disease in two brothers. (A) EKG in a 55-year-old male showing a pattern of apical hypertrophy. (B) Apical transthoracic
view showing an apical hypertrophy (arrow). (C) CMR finding of predominantly apical hypertrophy. (D) Inferolateral late gadolidium enhancement.
(E) EKG in his young brother showing milder but similar abnormalities. (F) Concentric diffuse hypertrophy in the brother. RV, right ventricle; LV, left
ventricle; LA, left atrium; RA, right atrium.
1091o G. Habib et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcim
aging/article-abstract/18/10/1090/3828464 by guest on 06 June 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
guidelines115 mainly due to the high variability of [18F]FDG uptake in
the normal myocardium, that requires adequate patient preparation
to prevent errors. Strategies for myocardial suppression to maximize
the accuracy of the procedure include prolonged fasting, dietary
modifications, and a heparin load before imaging.116 The imaging
protocol includes preferable gated cardiac [18F]FDG and whole
body images.117 A cardiac perfusion scan could be combined to com-
pare [18F]FDG-PET and perfusion patterns (Table 4).118
Pitfalls in [18F]FDG PET/CT imaging are myocarditis, CA, infec-
tion, and myocardial metastases, causing focal [18F]FDG uptake.
There are very few circumstances under which [18F]FDG will be
falsely negative as in case of corticosteroids treatment or ‘old, non-
active’ sarcoidosis.
[18F]FDG-PET/CT sensitivity and specificity for CS have been re-
ported at 89% and 78%, respectively.114 Quantitative analysis further
improved these figures, reaching a sensitivity of 97.3% and a specificity
of 83.6% for the diagnosis of CS. In addition, standardized uptake value
(SUVmax) on [18F]FDG-PET/CT was found the only independent
predictor among clinical and imaging variables for diagnosing CS.119
Serial [18F]FDG-PET/CT imaging can be utilized to assess the re-
sponse to therapies. Decrease [18F]FDG uptake in cardiac lesions
following therapy has been reported in case of corticosteroid treat-
ment as well as immunosuppressive therapies.120,121 Figure 13 illus-
trates the value of serial [18F]FDG PET/CT in a patient with CS
treated with high dose corticosteroids.
[18F]FDG-PET/CT only moderately correlated with CMR, mainly
due to the different significance of findings: LGE by CMR represents car-
diac damage and scarring whereas [18F]FDG uptake represents active
inflammation. When CMR and [18F]FDG -PET/CT were compared
with the Japanese Ministry of Health and Welfare guidelines, CMR had a
higher specificity with lower sensitivity than nuclear imaging.122
In summary, [18F]FDG-PET/CT and CMR are powerful imaging
techniques for accurate detection and therapy monitoring of CS.
Protocols for imaging with these modalities are increasingly well
defined, however large prospective studies supporting new guidelines
for CS imaging are warranted.
Systemic sclerosis
Systemic sclerosis (SSc) is a connective tissue disease characterized
by vascular and fibrotic lesions of skin and internal organs and repre-
sents a model of progressive interstitial myocardial fibrosis triggered
Figure 12 Patient with known CS. The image shows a late gado-
linium enhanced CMR image in the vertical long axis plane. Several
focal areas of myocardial enhancement can be seen (arrows) con-
sistent with granulomatous myocardial infiltration.
....................................................................................................................................................................................................................
Table 4 Interpretation criteria by combining rest perfusion imaging and FDG findings in suspected cardiac sarcoid-
osis. Adapted from Blankstein et al118
Rest perfusion FDG Interpretation
Normal perfusion and metabolism
Normal No uptake Negative for CS
Normal Diffuse Diffuse FDG most likely due to suboptimal patient preparation
Abnormal perfusion or metabolism
Normal Focal Could represent early disease
Defecta No uptake Perfusion defect represents scar from sarcoidosis or other aetiology
Abnormal perfusion and metabolism
Defect Focal in area of perfusion defect Active inflammation with scar in the same location
Defect Focal on diffuse with focal in area of
perfusion defect
Active inflammation with scar in the same location with
either diffuse inflammation or suboptimal preparation
Defect Focal in area of normal perfusion Presence of both scar and inflammation in different segments
of the myocardium
CS, cardiac sarcoidosis.
aEpicardial coronary artery disease should be always ruled out in these patients, to avoid misinterpretation due to hibernating myocardium.
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..by increased endothelin production and also focal hypoperfusion.123
Cardiovascular involvement has been shown to be one of the leading
causes of mortality in SSc and can occur in up to 70% of patients as a
finding on autopsy.124,125 Although the primary myocardial involve-
ment remains clinically silent in the majority of patients, it can lead to
further diastolic and systolic LV dysfunction,126 which carries a poor
prognosis. Early diagnosis and accurate staging of myocardial involve-
ment are therefore crucial for the management of these patients and
for therapeutic strategies.
Conventional echocardiographic assessment of the LVEF has
shown limited sensitivity being able to identify only 5% of patients
with cardiac involvement.127 Results of studies using TDI and
speckle-tracking echocardiography suggested that myocardial vel-
ocity and strain might be more sensitive than conventional measures
in identifying subtle cardiac dysfunction in asymptomatic patients
with SSc.128,129
Since myocardial fibrosis is the primary abnormality underlying SSc
cardiac involvement, methods that enable early identification of fibro-
sis should be preferred. EMB is the gold standard for the detection of
myocarditis that may be found in SSc patients and might help to de-
tect cardiac involvement at an early stage of the disease as inflamma-
tion was found in 96% and fibrosis in 100% of all SSc patients
investigated.130 Importantly, prognosis was poor and associated with
the degree of cardiac inflammation and fibrosis revealing an event
rate of 28% within 22.5 months follow-up.130
CMR with LGE imaging has been used to detect myocardial areas
with replacement fibrosis in patients with an advanced stage of
SSc.131 However, at an early stage of the disease, myocardial fibrosis
in SSc is usually diffuse and thus, undetected by LGE-CMR. ECV esti-
mation using pre- and post-contrast T1 mapping has been used to
visualize increased collagen content in SSc.132 A recent study has
demonstrated that ECV imaging performed early during SS reveals
myocardial abnormalities consistent with diffuse myocardial fibrosis
that are not apparent on LGE imaging, therefore representing an
early marker of disease.133 In addition, the ECV abnormalities corre-
lated with diastolic LV dysfunction which occurred in 45% of the pa-
tients.134 This study also evaluated the systolic circumferential strain
by CMR that was also found decreased but without any correlation
with ECV increase, suggesting therefore that LV systolic dysfunction
may be related not only to myocardial fibrosis but also to other phe-
nomena, such as myocardial ischaemia.
In SSc, myocardial ischaemia, unrelated to coronary artery disease,
is common with impairment of microcirculation and coronary vaso-
spasm.135 Therefore, stress echocardiography, CMR stress perfusion
and SPECT have been proposed to evaluate myocardial perfusion in
SS patients
Non-familial/non-genetic RCM: radiation
therapy and cancer drug therapy induced
RCM
Cardiac toxicity of radiation therapy
In general, the development of radiotherapy-induced RCM suggests a
prior high-dose chest irradiation (>60 Gy). It can also occur at lower
Figure 13 Forty-one year-old male with a total AV block, bradycardia, and weakness. The patient was suspected of CS. Echocardiography was
normal. A FDG PET/CT was performed after careful patient preparation with a fatty diet and showed heterogeneous, spotty high uptake in the left
ventricle of the heart (left whole body PET and upper row right short axis PET/CT). The patient was treated with high-dose corticosteroids and the
repeated FDG PET/CT after 3 months shows fully normalization of the myocardium (right whole body FDG PET/CT and lower short axis PET/CT).
1091q G. Habib et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcim
aging/article-abstract/18/10/1090/3828464 by guest on 06 June 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..radiation exposure when anthracycline is used.136 RCM occurs as a
result of diffuse myocardial fibrosis. On echocardiography, the
classical features of RCM are found. Although its value in radiation-
related myocardial fibrosis is still unclear, ECV estimation using
pre- and post-contract T1 mapping by CMR is directly related to col-
lagen content.137 The presence of decreased mean LV mass, end-
diastolic dimension, and end-diastolic wall thickness together with
dilation of both atria and self-reported dyspnoea, is suggestive of
RCM in this population.138 Cardiac CT has little value in the diagnosis
of RCM after radiotherapy, except for the detection of any associated
vascular disease. There is no proven value of nuclear cardiology in
the detection of RCM after radiation exposure. However, perfusion
scintigraphy imaging can reveal fixed regional perfusion defects, which
possibly indicate direct damage and the presence of local fibrosis.139
Cancer drug induced RCM
The typical structural manifestation of cancer drug induced cardiomy-
opathy corresponds to a LV eccentric remodelling with dilation of in-
ternal cavity and thinning of myocardial walls.140 When clinical heart
failure is overt, this picture is associated with a significant reduction of
LV ejection fraction. In the more advanced stages, LV diastolic func-
tion can be strongly altered with an abnormal increase of LV filling
pressure. This will induce the classic ‘restrictive’ physiology with the
typical standard Doppler-derived transmitral pattern: E/A ratio > 2
or even > 3 and short E velocity deceleration time (usually < 150–
160 msec). The presence of a restrictive pattern in a patient with can-
cer drug induced cardiotoxicity has a recognized prognostic value,
exactly as this occurs in the general clinical setting.8
Currently, the restrictive diastolic pattern is detectable in particu-
lar in patients undergoing anthracyclines (Cardiotoxicity type 1), it
being possibly evident not only during treatment (acute cardiotoxic-
ity) but also—and more often—after the completion (even several
years after) of cancer therapies.140 (Figure 14, see Supplementary
data online, Videos S6 and S7). Early cardiotoxicity, occurring during
or within 1 year of completion of treatment, is the most important
risk factor for the development of late cardiotoxicity, which occurs
beyond a year of completion of treatment. This is very important to
know in children undergoing anthracyclines therapy. In fact, they can
develop late cardiotoxicity during adulthood and should be therefore
carefully monitored for years by echocardiography. Cumulative as
well as peak anthracycline doses affect adults and children alike.
The restrictive physiology of diastolic pattern is instead very rare
in patients undergoing trastuzumab therapy and similar drugs
(Cardiotoxicity type 2).140 This kind of cardiotoxicity is usually re-
versible with cancer therapy interruption. However, since trastuzu-
mab can be sequentially added to anthracyclines, a combined effect
anthracyclinesþ trastuzumab on the degree of LV filling pressures
cannot be excluded and should therefore be carefully monitored.
When a restrictive LV diastolic pattern is detectable in patients
receiving cancer drugs, the echocardiographic exam should be ex-
tended to a quantitative evaluation of LV longitudinal function. In fact,
when high levels of LV filling pressure are evident, a reduction of GLS,
measurable by speckle tracking echocardiography, is usually observed.
If speckle tracking echocardiography is not available, pulsed tissue
Doppler-derived s’ velocity of the mitral annulus or even the simple M-
mode derived mitral annular plane systolic excursion represent much
more than simple surrogates of LV longitudinal dysfunction.
Figure 14 Twenty-five year-old woman treated for Hodgkin disease in infancy with anthracyclins. Chest X ray (1) and echocardiography (2 and 3)
show a non-dilated left ventricle, with a relatively preserved LV contractility (Supplementary data online, Video S6). However, mitral flow (4) and pul-
monary venous flow (5) show a severely restrictive pattern and tricuspid flow recording (6) reveals pulmonary hypertension. Severe longitudinal dys-
function is evidenced by two-dimensional strain (Supplementary data online, Videos S6 and S7).
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..In this cohort of patients, CMR can be useful both for the accurate
volumetric assessment with cine imaging but also with the LGE tech-
nique for the detection of myocardial fibrosis,140 i.e. the first deter-
minant of LV diastolic dysfunction and LV filling pressure increase.
Endomyocardial RCMs
Endomyocardial fibrosis
EMF is an often-neglected disorder in the tropical and subtropical re-
gions of the world which is characterized by the development of a
RCM,141 and is associated with a high morbidity and mortality.142 As
etiologic causes of EMF, infections, inflammation, allergy, malnutrition,
and toxic agents are discussed.143 At the histological level, EMF is
characterized by a marked endocardial thickening due to the depos-
ition of fibrous tissue (Figure 15).144
An echocardiographic examination of 1063 individuals revealed
that most subjects (55%) had a biventricular involvement, and 28%
revealed a right-sided prevalence with mild-moderate structural and
functional echocardiographic abnormalities.145
Regarding the diagnosis of EMF, transthoracic echocardiographic
changes can be useful for visualizing structural abnormalities, espe-
cially in chronic EMF.142,144 The main echocardiographic features in-
clude apical obliteration of the left and/or right ventricles, reduced
volume of the ventricular cavity, endocardial thickening and a restrict-
ive pattern. (Figure 16, see Supplementary data online, Video S8)
EMF may be difficult to differentiate from other cardiomyopathies
(Loeffler’s endocarditis, Churg–Strauss syndrome or rheumatoid
arthritis, tuberculous pericarditis, CP, or apical HCM).142,146–148
After initial echocardiographic analysis, CMR149 including LGE
imaging should be performed which is now the gold standard for
imaging the disease. (Figure 17) In a CMR study of 36 patients, it was
shown that LGE-CMR can provide detailed information on ventricu-
lar morphology, including the existence of thrombus or calcifications,
and revealing functional information which is useful in the diagnosis
and prognosis of EMF through quantification of the typical pattern of
the endocardial fibrous tissue deposition.150 Adjunctive diagnostic
tools, such as EMB, can be considered in ambiguous cases151 and can
help in patient management.
Hypereosinophilic syndrome
Eosinophilic EMF is a rare cause of RCM, resulting from toxicity of eo-
sinophils towards cardiac tissues.152 The causes for eosinophilic infil-
tration of myocardium are hypersensitivity, parasitic infestation,
systemic disease, myeloproliferative syndrome, and idiopathic hyper-
eosinophilic syndrome.152
Cardiac disease follows three stages with involvement of the endo-
cardium, the myocardium, and the pericardium. The first is eosino-
philic myocarditis (acute necrotic stage) due to infiltration of
eosinophils and release of the contents of their granules in the
myocardium.152 There is no relationship between the extent of the
infiltrate and clinical symptoms.153 The intermediate phase is the
thrombotic stage, characterized by mural thrombi along the damaged
endocardium (more often in the apex of the left ventricle). The third
stage is the later fibrotic stage in which the granulation tissue is
changed into hyaline fibrosis. The endocardial scar can result in a de-
crease of ventricular compliance and in RCM.154
Figure 15 Histologic finding in a patient with EMF.
1091s G. Habib et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcim
aging/article-abstract/18/10/1090/3828464 by guest on 06 June 2019
..
..
..
..
..
..
..
..
..On echocardiography, classical findings are progressive endo-
myocardial thickening, apical obliteration of one or both ventricles
by echogenic material suggestive of fibrosis or thrombus forma-
tion, posterior mitral leaflet involvement and papillary dysfunction
resulting in mitral regurgitation.154,155 (Figure 18A). Pericardial ef-
fusion can be present as well as the typical RCM pattern of
normal-to-small ventricles with large atria.156 Echocardiography
can also be useful for monitoring the effects of specific therapies
on the reversal of endomyocardial infiltration in hypereosinophilic
cardiomyopathy.157
CMR is very useful in EMF, both for diagnosis of endocardial in-
volvement and for detection of thrombus formation in both
Figure 17 LV EMF in a 58-year-old man presenting with congestive heart failure. (A) Cine four chamber view in end-diastolic phase showing a
thickening of LV apex (black arrow), a reduced volume of the LV cavity and a left atrial enlargement. (B) LGE four chambers view showing a marked
endocardial thickening with late gadolinium enhancement (black arrow) and an apical thrombus (open arrow).
Figure 16 (A) (TTE) and (B) (CMR) Right ventricular EMF in a 50 year-old woman (Supplementary data online, Video S8). The apex of the right
ventricle is obliterated (white arrow), with subsequent surgical confirmation. RA, right atrium; RV, right ventricle; LV, left ventricle; LA, left atrium.
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ventricles158–161 (Figure 18B). The gold standard is EMB but the high
resolution of CMR and transthoracic echocardiography (TTE) is fre-
quently sufficient for diagnosis and follow-up.3
Carcinoid heart disease
Carcinoid heart disease occurs in 20–70% of patients with metastatic
carcinoid tumours and will lead to increased morbidity and mortality in
these patients.162 The endocardial fibrosis results in retraction and fix-
ation of the heart valves. Right-sided valves are mainly affected.163 Left-
sided valvular pathology occurs in approximately 10% of patients with
carcinoid heart disease and is associated with right-to-left shunting,
bronchial carcinoid, or poorly controlled carcinoid syndrome.164,165
The hallmarks of carcinoid heart disease are a combination of
right-sided valvular dysfunction and typical morphological changes of
the valves like valve leaflet thickening, shortening, retraction, reduced
mobility, or incomplete coaptation of the tricuspid leaflets.166–168
CMR has an additive value in carcinoid heart diseases, especially
when echocardiography is inconclusive and for accurate measure-
ments of right ventricular function and assessment of carcinoid pla-
ques using LGE.168 Figure 19 and Supplementary data online, Videos
S9 and S10 illustrate the value of multimodality imaging in a patient
with carcinoid heart disease.
Drug-induced EMF
Animal data suggest the possibility of drug-induced EMF induced by
5-HT2B serotonin receptor agonists such as fenfluramine derivatives,
pergolide, cabergolide, and methysergid and ergotamine,169–171 but
very scarce data are currently reported in man. Indeed, only one case
of RCM is reported after fenfluramine-phentermine exposure.172 In
addition, a case of sub-aortic obstruction within the LV outflow tract
related to drug-induced EMF has been recently reported in a patient
exposed to benfluorex, an agonist of 5-HT2B serotoninergic
receptors.173
Differential diagnosis between
RCM and other cardiac diseases
Differential diagnosis between RCM and
CP
Differential diagnosis between RCM and CP can be a challenge as
their clinical presentation is relatively similar with right heart fail-
ure symptoms, preserved LV ejection fraction, and diastolic dys-
function. However, as the treatment of these two conditions is
very different, constriction being potentially curable by surgery,
making the correct diagnosis is critically important. The differen-
tial diagnosis could be performed particularly using the comple-
mentary elements obtained from TTE, CMR, cardiac CT, or
cardiac catheterization. (Table 5)
Cardiac catheterization was the first method historically used to
help in the differential diagnosis of RCM and CP, but is not always
conclusive.174,175
In both RCM and CP, biatrial dilatation, venous dilatation as well as
pericardial effusion can be observed. Several echocardiographic par-
ameters have been identified to differentiate myocardial diseases
from pericardial constriction.10,176 In case of RCM, some degree of
LV or biventricular hypertrophy or unusual echo texture can be
noted (RCM of infiltrative origin). In case of CP, pericardial thickening
(>3 mm) or hyperechogenicity of the pericardium can be observed.
But one of the main characteristics of CP is the absence of transmis-
sion of the intrathoracic pressure variations to the heart, which are
physiologically present during the respiratory cycle.
Both TTE and real-time cine CMR allow the identification of some
key findings which differentiate the two pathologies: septal bulging
occurring with cavity volume variations and the exaggerated
respiratory-related LV-RV coupling highlighted by a respiratory septal
shift observed in CP and a significant respiratory variation of the dia-
stolic flow. The respiratory septal shift is defined by a difference in the
maximal septal excursion into LV between inspiration and expiration
(Supplementary data online, Video S11).176 Using CMR, this parameter
has a sensitivity of 80% and specificity of 100% to detect CP.17
Other echocardiographic findings have been reported to be useful
for differentiating RCM and CP, including TDI (e’), E velocity deceler-
ation time, pulmonary vein flow, left atrial volume, and E/e’ ratio.177
Figure 20 shows an algorithm proposed by the recent ASE/EACVI
recommendations for the evaluation of diastolic function by echocar-
diography,8 comparing CP and RCM. The presence of a normal annu-
lar e’ velocity in a patient referred with heart failure diagnosis should
raise suspicion of pericardial constriction.8
LV myocardial velocities.178–181 and deformation11 measured by
both TTE and CMR182 are reduced at a greater degree in RCM com-
pared to CP. Both echocardiography and CMR provide concordant
diagnostic information and incremental value for differentiating CP
from RCM. Complementary assessment of structural (pericardial
thickening), mechanical (myocardial velocities and strains) and hae-
modynamic (respiratory septal shift) by both TTE and CMR increase
the cost-efficacy and confidence for the diagnosis of RCM vs. CP.
Cardiac CT provides excellent anatomic delineation of the pericar-
dium, allowing for accurate measurement of pericardial thickness (ab-
normal if > 4mm),183 although a normal pericardial thickness does
not exclude CP.184 Cardiac CT is superior to CMR in detecting peri-
cardial calcifications.185 Finally, multimodality imaging should be per-
formed in patients with suspected CP, since each imaging modality
presents with both advantages and limitations (Table 5, Figure 21)
In summary, the differentiation between RCM and CP is frequently
difficult and should take into account both clinical presentation and
multimodality imaging. The absence of pericardial thickening does
not rule out CP. Echocardiography, CMR, and CT provide comple-
mentary information and in many patients all three should be per-
formed when CP is suspected.
Differential diagnosis or association
between RCM and other myocardial
diseases
Although in its most typical « apparently idiopathic » form, RCM pre-
sents without LV hypertrophy, in some patients, some forms of car-
diomyopathy may resemble or be associated with RCM. Particularly,
HCM may resemble RCM in some patients. The classical HCM
phenotype presents with enhanced contractility, small cavity,
reduced indexed stoke volume, LVOT obstruction, Grade 1 diastolic
dysfunction with some fibrosis.186,187 As the disease progresses,
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Figure 18 (A) Multimodality imaging in hypereosinophilic syndrome with cardiac involvement showing severe restriction of the posterior mitral
leaflet associated with involvement of the subvalvular apparatus and severe mitral regurgitation by echocardiography (a, b) and CMR (C) with worsen-
ing in the follow-up (D) From reference 155 with permission. RA, right atrium; RV, right ventricle; LV, left ventricle; LA, left atrium. (B) CMR in a pa-
tient with hypereosinophilic syndrome and Loeffler’s syndrome. Cine image (still frame) (A) demonstrates a dilated left ventricle and moderate
pericardial effusion (asterisks). T2-weighted image (B and C) shows subendocardial high-signal intensity suggestive of inflammation (white arrows),
and T1-weighted images after contrast administration (D–F) demonstrate endocardial fibrosis (arrowheads). Of note, an RV apical thrombus is evi-
dent in the cine image and in the T1-weighted sequences (triangles) (from 159 with permission).
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extensive fibrosis,52 reduced systolic function,52 diastolic dysfunc-
tion,188,189 marked dilatation of the atria,190 relative thinning of the
LV walls, loss of LVOT obstruction,190–192 and pulmonary hyperten-
sion192 dominate the picture, mimicking RCM.
Isolated LV non-compaction is a rare form of cardiomyopathy,193
which should also be differentiated from RCM, but is also sometimes
associated with a restrictive pattern or even a true RCM194 (Figure
22, Supplementary data online, Video S12)
Conclusion and future directions
RCM represents a heterogeneous group of cardiac diseases with dif-
ferent pathophysiological processes, clinical presentation, treatment,
and prognosis. The two main objectives of the clinician are to rule
out CP and to find a potentially treatable cause of RCM. Imaging
techniques including echocardiography, cardiac CT, CMR, and nu-
clear techniques are of utmost value for the diagnostic and prognos-
tic assessment of RCM. These techniques give additional information
and should frequently be used in combination in the same patient to
maximize diagnostic performance. Finally, additional investigations
such as EMB, familial screening, and genetic studies are frequently ne-
cessary in these patients. For these reasons, patients with suspected
RCM should be referred to specialized centres that can provide mul-
timodality imaging and a multidisciplinary team approach.
Supplementary data
Supplementary data are available at European Heart Journal—
Cardiovascular Imaging online.
Conflict of interest: None declared.
Figure 19 Carcinoid disease with right heart involvement. (A) (TTE) and (C) (CMR): restriction of the movements of the tricuspid leaflets, which
are thickened. The right ventricle myocardium is also involved. (B) Massive tricuspid regurgitation (TTE). (C) CMR showing dilatation of right heart
cavities and restricted tricuspid leaflet (arrow) (Supplementary data online, Videos S9 and S10). RA, right atrium; RV, right ventricle; LV, left ventricle;
LA, left atrium.
1091w G. Habib et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcim
aging/article-abstract/18/10/1090/3828464 by guest on 06 June 2019
Figure 20 ASE/EACVI algorithm comparing CP and RCM. From 8 with permission.
....................................................................................................................................................................................................................
Table 5 Multimodality imaging to differentiate RCM from constrictive pericarditis
Constrictive pericarditis RCM
Chest X-ray
Pericardial calcification þþþ rare
Two-dimensional and M-mode echocardiography
Abrupt septal movement (‘notch’ or ‘bounce’) in early diastole þþþ 0
Septal movement toward left ventricle in inspiration þþþ 0
Left atrial enlargement þ þþþ
Thick pericardium þþþ 0
Pulsed-wave Doppler
Respiratory variation in mitral and tricuspid flow velocity >25% <15%
Diastolic flow reversal in expiration within the hepatic vein þþþ þ
TDI
Mitral medial annulus velocities e’ > 8 cm/s, E/e’ < 15 e’ < 8 cm/s, E/e’ > 15
Deformation imaging
Reduced longitudinal strain 0 þþ
Cardiac CT/CMR
Thick pericardium (cardiac CT) þþþ 0
Pericardial calcifications (cardiac CT) þþþ 0
Left atrial enlargement (cardiac CT/CMR) þ þþþ
Abrupt septal movement (‘notch’ or ‘bounce’) in early diastole (CMR) þþþ 0
Septal movement toward left ventricle in inspiration (CMR) þþþ 0
Reduced longitudinal strain (CMR) 0 þþ
RCM, restrictive cardiomyopathy; TDI, tissue Doppler imaging; CMR, cardiovascular magnetic resonance; CT, computed tomography.
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